← Human Trials & Peer-Reviewed Studies
Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon
Plain-language guide to PMID 1978025 (1990): parallel-group controlled clinical trial study of Endothelin-1 in 7 subjects, raynaud's.
Key Facts
- PMID
- 1978025
- Journal
- Lancet (London, England)
- Year
- 1990
- Study type
- Controlled Clinical Trial
- Authors
- Zamora MR et al. (4 authors)
- DOI
- 10.1016/0140-6736(90)92766-b
What This Study Did, in Plain Language
What Was Tested
Researchers studied Endothelin-1 in the context of raynaud's in this controlled clinical trial publication.
Baseline serum ET-1 levels (pg/ml), as measured by radioimmunoassay, were three times higher in Raynaud's subjects (5.3 [SEM 1.7] pg/ml) than in controls (1.7 [0.3]).
With progressive local cooling digital arterial pulsatility, as measured by plethysmography, fell earlier and to a greater extent in Raynaud's subjects than in controls, with a half-maximum decrement in pulsatility occurring at 27 [2.6] degrees C and 18 [0.5] degrees C, respectively.
Who Took Part
The abstract describes 7 subjects taking part.
The age groups tagged for this paper are adults, women only.
How the Study Was Run
The researchers set it up as a parallel-group study.
The Endothelin-1 group and the comparison group ran side by side rather than switching.
What Was Measured
Baseline serum ET-1 levels (pg/ml), as measured by radioimmunoassay, were three times higher in Raynaud's subjects (5.3 [SEM 1.7] pg/ml) than in controls (1.7 [0.3]).
With progressive local cooling digital arterial pulsatility, as measured by plethysmography, fell earlier and to a greater extent in Raynaud's subjects than in controls, with a half-maximum decrement in pulsatility occurring at 27 [2.6] degrees C and 18 [0.5] degrees C, respectively.
The subject headings attached to it are Body Temperature, Cold Temperature, Endothelins, Pulse, Radioimmunoassay, Raynaud Disease and Vasoconstriction.
What This Means in Plain Language
The paper is a parallel-group study of Endothelin-1 in 7 subjects in people with raynaud's.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1990 (Lancet (London, England)), a journal based in England.
More context: the Endothelin-1 compound page, Raynaud's research.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.